QQQ

DIA

SPY

TLT

GLD

BTC/USD

QQQ

DIA

SPY

TLT

GLD

BTC/USD

Range

2.9 - 3.04

Vol / Avg.

362.2K/921.1K

Div / Yield

-

52 Wk

2.67 - 5.7

Mkt Cap

347.6M

Payout Ratio

-

Open

2.91

P/E

-

EPS

-0.16

Shares

116.6M

Outstanding

116.6M

Total Float

70.1M

Analyst Ratings

Selecta Biosciences, Sobi Report Completion Of Enrollment In DISSOLVE Phase 3 Study Evaluating SEL-212 For Chronic Refractory Gout

Benzinga - 1 day ago

Selecta's Gene Therapy Trial For Genetic Metabolic Disorder Put On FDA Hold

Benzinga - 6 days ago

Selecta Biosciences Shares Resume Trade, Move Sharply Lower, Down 17%

Benzinga - Nov 24, 2021, 4:45PM

Selecta Biosciences Shares To Resume Trade 4:45 p.m. EST

Benzinga - Nov 24, 2021, 4:40PM

Selecta Biosciences Announces FDA Has Issued Clinical Hold On Phase 1/2 Clinical Trial Of SEL-302 Due To CMC Related Questions

Benzinga - Nov 24, 2021, 4:16PM

Selecta Biosciences Shares Halted News Pending

Benzinga - Nov 24, 2021, 4:10PM

Selecta Biosciences Q3 EPS $(0.16) Misses $(0.07) Estimate, Sales $24.43M Beat $12.19M Estimate

Benzinga - Nov 9, 2021, 8:42AM

Selecta Biosciences Posts Encouraging Data For ImmTOR Platform

Benzinga - Nov 8, 2021, 12:39PM

Selecta Biosciences Announces Top Line Data From Phase I SEL-399 AAV Empty Capsid Study; No Serious Adverse Events Reported, At Day 30 100% Of Subjects In 0.3mg/kg ImmTOR Cohort Showed NAb titers Of ≤ 1:25 And 67% showed NAb Titers Of ≤ 1:5

Benzinga - Nov 8, 2021, 8:18AM

UPDATE: Needham On Selecta Biosciences Price Target Bump: Firm 'Estimates 30% Upside On Best Scenario' With Positive Bias For Data Readout Given Preclinical Data; Sees SEL-399 Readout 'On Track For This Quarter' & May Be A Significant Value Driver

Benzinga - Nov 1, 2021, 10:36AM

Needham Maintains Buy on Selecta Biosciences, Raises Price Target to $7

Benzinga - Nov 1, 2021, 6:23AM

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

Benzinga - Oct 26, 2021, 12:15PM

Selecta Biosciences shares are trading higher after the company reported a partnership with Ginkgo Bioworks to advance treatments for orphan and rare diseases.

Benzinga - Oct 26, 2021, 8:23AM

Selecta Biosciences Reports Partnership With Ginkgo Bioworks To Advance Treatments For Orphan, Rare Diseases

Benzinga - Oct 26, 2021, 8:01AM

Selecta In-Licenses Rights To IgG Protease Platform

Benzinga - Oct 21, 2021, 9:50AM

Selecta Biosciences Reports Exclusive License Deal With Genovis To Advance Next-Gen Immunoglobulin Protease In Gene Therapy, Autoimmune Disease, No Terms Disclosed

Benzinga - Oct 21, 2021, 8:01AM

Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit Oct. 27-28

Benzinga - Oct 20, 2021, 8:21AM

Select Biosciences To Present New Data For ImmTOR Platform At ESGCT 28th Annual Congress On Oct. 19-22

Benzinga - Oct 13, 2021, 8:14AM

UPDATE: Selecta Biosciences And Takeda Announce Under The Terms Of The Agreement, Selecta Is Entitled To Receive An Undisclosed Upfront Payment And Up To $1.124B In Future Additional Payments Over The Course Of The Partnership

Benzinga - Oct 4, 2021, 8:38AM

Selecta Biosciences Announces Strategic Licensing Agreement With Takeda To Develop Next-Generation Gene Therapies For Patients With Lysosomal Storage Disorders

Benzinga - Oct 4, 2021, 8:37AM

Selecta Biosciences Announces Appointment Of Kevin Tan As Chief Financial Officer

Benzinga - Sep 20, 2021, 8:21AM

Selecta Biosciences shares are trading higher after the company reported better-than-expected Q2 sales.

Benzinga - Aug 12, 2021, 8:52AM

load more

Sector: Health Care.Industry: Biotechnology

Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Earnings

Q3 2021		Est.		Actual		Surprise
EPS		-0.070		-0.160		-0.0900
REV		12.190M		24.427M		12.237M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Selecta Biosciences Questions & Anwsers

Q

How do I buy Selecta Biosciences (SELB) stock?

A

You can purchase shares of Selecta Biosciences (NASDAQ: SELB) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Selecta Biosciences's (SELB) competitors?

A

Other companies in Selecta Biosciences’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), KalVista Pharmaceuticals (NASDAQ:KALV) and Ambrx Biopharma (NYSE:AMAM).

Q

What is the target price for Selecta Biosciences (SELB) stock?

A

The latest price target for Selecta Biosciences (NASDAQ: SELB) was reported by Needham on November 1, 2021. The analyst firm set a price target for 7.00 expecting SELB to rise to within 12 months (a possible 134.90% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Selecta Biosciences (SELB)?

A

The stock price for Selecta Biosciences (NASDAQ: SELB) is $2.98 last updated Today at 5:08:16 PM.

Q

Does Selecta Biosciences (SELB) pay a dividend?

A

There are no upcoming dividends for Selecta Biosciences.

Q

When is Selecta Biosciences (NASDAQ:SELB) reporting earnings?

A

Selecta Biosciences’s $Q3 earnings are confirmed for after-market on November 9, 2021.

Q

Is Selecta Biosciences (SELB) going to split?

A

There is no upcoming split for Selecta Biosciences.

Q

What sector and industry does Selecta Biosciences (SELB) operate in?

A

Selecta Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.